Vaccines for colorectal cancer

Herbert J. Zeh, Kevin Stavely-O'Carroll, Michael A. Choti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Despite recent advances in the treatment of colorectal cancer, the overall survival rate for those patients with advanced locoregional disease remains less than 50%. Although adjuvant systemic chemotherapy has improved survival of these patients, more effective therapies are needed. Immunotherapy is an approach that could have a particular role in the adjuvant therapy of colorectal cancer. There is now convincing evidence that the immune system can specifically recognize and destroy malignant cells. Although both antibody- and T-cell-mediated anti-tumor responses have been documented, the cellular immune response with its direct cytotoxic mechanisms is felt to be the principal anti-tumor arm of the immune system. Analysis of the T cells that recognize tumors has led to the identification and characterization of many tumor-associated antigens including several colorectal antigens. Current approaches to developing a vaccine for colorectal cancer use our expanded understanding of these tumor-associated antigens and the conditions that allow development of an effective cellular immune response to them.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalTrends in Molecular Medicine
Volume7
Issue number7
DOIs
StatePublished - 2001

Fingerprint

Colorectal Neoplasms
Vaccines
Neoplasm Antigens
Cellular Immunity
Immune System
T-Lymphocytes
Neoplasms
Adjuvant Chemotherapy
Immunotherapy
Therapeutics
Survival Rate
Antigens
Survival
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vaccines for colorectal cancer. / Zeh, Herbert J.; Stavely-O'Carroll, Kevin; Choti, Michael A.

In: Trends in Molecular Medicine, Vol. 7, No. 7, 2001, p. 307-313.

Research output: Contribution to journalArticle

Zeh, Herbert J. ; Stavely-O'Carroll, Kevin ; Choti, Michael A. / Vaccines for colorectal cancer. In: Trends in Molecular Medicine. 2001 ; Vol. 7, No. 7. pp. 307-313.
@article{4e5268ad77d54b319820f301eade784f,
title = "Vaccines for colorectal cancer",
abstract = "Despite recent advances in the treatment of colorectal cancer, the overall survival rate for those patients with advanced locoregional disease remains less than 50{\%}. Although adjuvant systemic chemotherapy has improved survival of these patients, more effective therapies are needed. Immunotherapy is an approach that could have a particular role in the adjuvant therapy of colorectal cancer. There is now convincing evidence that the immune system can specifically recognize and destroy malignant cells. Although both antibody- and T-cell-mediated anti-tumor responses have been documented, the cellular immune response with its direct cytotoxic mechanisms is felt to be the principal anti-tumor arm of the immune system. Analysis of the T cells that recognize tumors has led to the identification and characterization of many tumor-associated antigens including several colorectal antigens. Current approaches to developing a vaccine for colorectal cancer use our expanded understanding of these tumor-associated antigens and the conditions that allow development of an effective cellular immune response to them.",
author = "Zeh, {Herbert J.} and Kevin Stavely-O'Carroll and Choti, {Michael A.}",
year = "2001",
doi = "10.1016/S1471-4914(01)01992-X",
language = "English (US)",
volume = "7",
pages = "307--313",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Vaccines for colorectal cancer

AU - Zeh, Herbert J.

AU - Stavely-O'Carroll, Kevin

AU - Choti, Michael A.

PY - 2001

Y1 - 2001

N2 - Despite recent advances in the treatment of colorectal cancer, the overall survival rate for those patients with advanced locoregional disease remains less than 50%. Although adjuvant systemic chemotherapy has improved survival of these patients, more effective therapies are needed. Immunotherapy is an approach that could have a particular role in the adjuvant therapy of colorectal cancer. There is now convincing evidence that the immune system can specifically recognize and destroy malignant cells. Although both antibody- and T-cell-mediated anti-tumor responses have been documented, the cellular immune response with its direct cytotoxic mechanisms is felt to be the principal anti-tumor arm of the immune system. Analysis of the T cells that recognize tumors has led to the identification and characterization of many tumor-associated antigens including several colorectal antigens. Current approaches to developing a vaccine for colorectal cancer use our expanded understanding of these tumor-associated antigens and the conditions that allow development of an effective cellular immune response to them.

AB - Despite recent advances in the treatment of colorectal cancer, the overall survival rate for those patients with advanced locoregional disease remains less than 50%. Although adjuvant systemic chemotherapy has improved survival of these patients, more effective therapies are needed. Immunotherapy is an approach that could have a particular role in the adjuvant therapy of colorectal cancer. There is now convincing evidence that the immune system can specifically recognize and destroy malignant cells. Although both antibody- and T-cell-mediated anti-tumor responses have been documented, the cellular immune response with its direct cytotoxic mechanisms is felt to be the principal anti-tumor arm of the immune system. Analysis of the T cells that recognize tumors has led to the identification and characterization of many tumor-associated antigens including several colorectal antigens. Current approaches to developing a vaccine for colorectal cancer use our expanded understanding of these tumor-associated antigens and the conditions that allow development of an effective cellular immune response to them.

UR - http://www.scopus.com/inward/record.url?scp=0034953091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034953091&partnerID=8YFLogxK

U2 - 10.1016/S1471-4914(01)01992-X

DO - 10.1016/S1471-4914(01)01992-X

M3 - Article

C2 - 11425639

AN - SCOPUS:0034953091

VL - 7

SP - 307

EP - 313

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 7

ER -